Comparative Pharmacology
Head-to-head clinical analysis: CHROMITOPE SODIUM versus DRAXIMAGE DTPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMITOPE SODIUM versus DRAXIMAGE DTPA.
CHROMITOPE SODIUM vs DRAXIMAGE DTPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
None Documented
None Documented
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical